Navigation Links
Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
Date:4/14/2011

WALTHAM, Mass., April 14, 2011 /PRNewswire/ -- Proteon Therapeutics, Inc. has initiated enrollment in a Phase 2 clinical study of its lead product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis. This study follows successful completion of a 66-patient, double-blind, placebo-controlled Phase 1/2 study of PRT-201 in AVF patients that completed enrollment in July 2010.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in CKD patients, and we are very excited about the potential for PRT-201 to dramatically improve care for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon.  

The results of this Phase 2 study will be provided to Novartis under an agreement entered into in 2009, whereby Novartis was granted an exclusive option to acquire Proteon following the completion of a Phase 2 clinical study of PRT-201. Including the initial acquisition payment plus potential regulatory milestone payments, the acquisition deal with Novartis could exceed $550 million.

About PRT-201

PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) and arteriovenous graft (AVG) outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown in certain preclinical settings to reduce neointimal hyperplasia formation, and to cause dilation of segments of arteries and veins following topical intraoperative application. These effects may decrease the number of interventions necessary to maintain AVF and AVG patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for dialysis patients. The development program to investigate PRT-201 for
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... Nokia,s new website, which provides innovative ways to interact with thought ... , ... San Francisco, CA (PRWEB) February 12, 2009 -- ... genetic testing service 23andme, says that as we further our understanding ...
... OriGene Technologies, Inc. ("OriGene") today announced it ... private equity financing. With this financing, OriGene completed ... Shenzhen P&A Biotech, a manufacturer and provider of ... this acquisition OriGene completes the establishment of its ...
... for the control of parasites in agriculture and medicine, today announced that ... will further its efforts to create solutions for one of the major ... ... (PREWB) February 11, 2009 -- Biotechnology firm Divergence, Inc., a world leader ...
Cached Biology Technology:Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 2Famed IT Investor and Director of 23andme Esther Dyson Identifies on IdeasProject.com Genetic Information as an Extremely Disruptive Force 3OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China 2Divergence Raises $11.8 Million in Series C Financing 2Divergence Raises $11.8 Million in Series C Financing 3
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... illegal in many countries as it can be contaminated ... milk, making it taste bitter and turn thick and ... that can grow at low temperatures, spoiling raw milk ... in the November issue of the International Journal ...
... measurements in global climate studies University of Iowa researchers ... estimates of the amount of carbon absorbed by plants from ... land cover change estimates, according to a paper published in ... By knowing the effects of plants on the atmosphere, ...
... the open ocean may force scientists to rethink their understanding ... A paper describing the new findings appears in the November ... research team led by Jonathan Zehr, a marine scientist at ... by analyzing its genetic material, even though researchers have not ...
Cached Biology News:New bacteria discovered in raw milk 2New bacteria discovered in raw milk 3UI researchers help to improve carbon measurements in global climate studies 2Mysterious microbe plays important role in ocean ecology 2Mysterious microbe plays important role in ocean ecology 3
... been optimized for the analysis of SearchLight® ... to quickly and accurately locate and quantify ... ELISA plate or each section of a ... customized to incorporate standard ELISA analysis features, ...
... dual strength adhesive system which facilitates the easy ... on either side of the frame are of ... glass has an easy release adhesive whereas the ... stronger bond. This means that when the coverslip ...
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
Biology Products: